Repel. Eliminate. Protect.
Every year, millions of vascular access patients face preventable complications from Central Line-Associated Bloodstream Infection (CLABSI) and clotting.
Trinity Vascular Technologies was founded to change that by bringing a clinically proven, patent-protected surface technology to the devices that need it most.
Advancing Infection Prevention in Vascular Access
Trinity Vascular Technologies has developed a differentiated triple-action antimicrobial surface platform for vascular access devices and is advancing toward regulatory clearance and commercialization.
We address one of healthcare’s most persistent and costly challenges: catheter-related bloodstream infections.
The Clinical & Economic Imperative
Why Now? Hospitals Bear the Financial Risk
-
~250,000+ CLABSI cases annually in the U.S.
-
$40,000–$75,000+ incremental cost per infection — largely borne by hospitals
-
Increased ICU stays, mortality, and litigation exposure
-
CMS HAC Reduction Program penalizes worst performers by 1% of total Medicare inpatient payments
The Economic Problem
-
Medicare & Medicaid do not reimburse hospital-acquired infection costs
-
The $40,000–$75,000 per case directly impacts hospital margins
-
Poor performance can reduce CMS reimbursement across all admissions (5+ million in annual lost revenue per hospital)
Our Technology Platform
Best-in-class Triple-action Antimicrobial Strategy
Trinity Vascular Technologies developed a scalable triple-action antimicrobial surface platform designed for next-generation vascular access devices, including central venous catheters (CVC).
Bacterial colonies from existing CVC (left) vs. our CVC (right)
Zwitterionic Anti-fouling Surface
Surface chemistries incorporated into FDA-cleared medical devices, reducing microbial adhesion and biofilm formation.
Clinically Established Antimicrobial Agents
Integration of FDA-approved antibiotic combinations with established efficacy in vascular access applications.
Synergistic Dual-Mechanism Design
Combines anti-fouling surface repulsion with localized antimicrobial activity to address both bacterial attachment and colonization.
Designed for scalable application across CVC, PICC, IV, and hemodialysis devices.
Market Opportunity
-
$1.7B U.S. vascular access market
-
Initial focus: short-term central venous catheters (CVC)
-
Expansion into PICC, peripheral IV, and dialysis categories
Trinity is currently raising capital.
With strong projected revenue growth through 2032, the company anticipates valuations consistent with leading medtech industry benchmarks and comparable revenue multiples.
Commercialization Strategy
Investment Opportunity
Access spectrum — PICC, hemodialysis, and peripheral IV — pursuing FDA clearance across each category.
Commercial scale can be achieved through GPO relationships and strategic distribution partners, validated by clinical adoption at leading academic medical centers.
Trinity's near-term focus targets the U.S. central venous catheter market, expanding progressively into the broader U.S. vascular access market and ultimately the global opportunity, a category that has consistently attracted significant strategic acquisition interest, as demonstrated by Teleflex's acquisition of Vidacare and AngioDynamics' acquisition of Navilyst Medical.
Phase 2 – Platform Expansion
The medtech catheter and vascular access space has demonstrated strong acquisition and strategic interest, as evidenced by transactions involving companies such as Access Vascular, Semprus BioSciences, and Pursuit Vascular — validating the commercial and strategic value of innovation in this category.
Market Validation — Comparable Transactions
Trinity has identified a clear FDA 510(k) route to market, enabling an efficient and capital-effective path to commercialization relative to more complex regulatory designations.
Regulatory Pathway
Trinity is currently raising a Seed Round from investors aligned with its mission and growth trajectory. Proceeds will fund key development milestones leading to FDA 510(k) clearance and commercial launch, with a target market entry by 2029. Successful execution of this roadmap positions Trinity for Series A financing or strategic partnership, creating a compelling path for value creation across the investor base.
Why Trinity
Trinity sits at the intersection of materials innovation, infection prevention, and hospital economics, a rare convergence that defines both the problem and the opportunity.
Catheter-related infections cost the U.S. healthcare system billions annually. Existing solutions address one dimension of the problem. Trinity's triple-action platform addresses three simultaneously — anti-infective, anti-thrombotic, and anti-biofilm — applied through a scalable manufacturing process compatible with the full range of vascular access devices.
The result is a platform with a defined regulatory pathway, validated scientific foundations, and a market structure that has repeatedly rewarded strategic acquirers.
Supported by Competitive Federal Research Funding
Strategic & Clinical Collaborations